ultra-rare-diseas focu allow alexion captur
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim apr
price data jul
rate updat jul
currenc amount express
valuat growth profit
methodolog valu compani
alexion pharmaceut ultra-rare-diseas focu allow
compani captur substanti price power area high
unmet need compani multi-billion-dollar drug soliri
approv disease-modifi treatment paroxysm
nocturn hemoglobinuria atyp hemolyt urem
syndrom potenti soliri expand
indic two product ultra-rar metabol
disord pipelin target orphan opportun think
alexion well posit retain lead statu nich
key soliri success strong price power drug
dramat life-sav effect pnh ahu patient compris
peopl north america europ despit
small popul soliri high price
annual need lifelong use quickli turn drug
blockbust alexion focus soliri label expans
complement-medi diseas receiv approv
subtyp myasthenia gravi anoth rare diseas
anoth pivot trial neuromyel optica spectrum disord
pipelin competit grow drug manufactur flock
lucr autoimmun market alexion first-mov statu
next-gener pipelin mitig risk addit firm
continu drive growth identif new
patient given lack awar mani ultra-rar diseas
grossli underdiagnos alexion special salesforc
strong entrench patient doctor rais barrier
entri allow maintain quasi-monopoli hold
diseas space
outsid complement inhibitor franchis alexion portfolio
includ strensiq hypophosphatasia kanuma lysosom
acid lipas defici acquisit wilson therapeut also
think soliri favor competit posit drive solid
financi result forese futur alexion high
degre product concentr key risk
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
special develop market drug
life-threaten medic condit blockbust product soliri
approv therapi paroxysm nocturn hemoglobinuria
atyp hemolyt urem syndrom two ultra-rar blood disord
recent approv gener myasthenia gravi strensiq kanuma
target ultra-rar metabol diseas alexion pipelin target area
high unmet need complement-medi disord
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit jul
updat fair valu estim per share
incorpor optimist sale
guidanc expect second-quart acquisit
valuat firm remain primarili driven
expans soliri franchis alexion profit
cash flow gener power continu grow
compani expand abroad broaden soliri reach
patient new indic averag model
compound annual top-lin growth littl
bottom-lin growth firm next five year
believ soliri franchis could see peak sale
billion global growth patient pnh ahu
potenti label expans addit autoimmun
indic think strensiq kanuma peak sale
potenti billion million respect
ultra-rare-diseas indic expect gross
margin stay around forecast period
oper margin could near next year
drug move pipelin compani
leverag salesforc across broader revenu base
execut restructur plan
given alexion product concentr believ
compani merit high uncertainti rate bull case
assum alexion succe expand soliri label
addit indic receiv littl pushback
payer allow firm captur high price point
drug multipl market case assum
peak sale billion fair valu estim
would increas roughli per share bear case
assum cost pressur payer threat
gener biolog forc alexion lower price lose
market share time also assum soliri label
includ current approv indic scenario
pipelin contribut futur sale soliri sale
peak less billion think compani
valu would fall per share
believ alexion patent-protect portfolio
ultra-rare-diseas drug well clinic develop
target addit indic area high unmet
alexion focu ultra-rare-diseas market allow
autoimmun metabol diseas target
compani drug pipelin disease-modifi
treatment option face dire prognos caus
diseas slightli differ patient pnh
ahu devast uncontrol activ
immun system specif part call complement
result chronic destruct red blood cell lead
blood clot organ failur thirty-f percent pnh
patient die within five year ahu patient
progress end-stag renal diseas lal-d
patient miss key enzym critic metabol
function case onset diseas start
birth patient die organ failur within year given
access alexion drug matter life death
mani alexion treat diagnos popul
per-pati cost astronom overal
burden countri healthcar system small
number affect patient extrem limit soliri
tout one expens drug world
price may vari countri countri estim
annual averag cost drug
around
per patient strensiq kanuma
price nontrivi annual sum
per patient respect howev drug
clear disease-modifi benefit help justifi high
price facilit reimburs payer public
privat addit mani patient alexion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
phase trial acknowledg alexion portfolio
antibodi soliri recombin protein strensiq
kanuma -- histor difficult
manufactur small-molecul drug howev
believ biosimilar manufactur develop
progress far enough end decad erod
current advantag emphas moat rate
rest alexion patent
brand competit mount intang
gener alexion first-mov statu pipelin
creat high barrier entri closest pipelin threat
alexion complement franchis phase
small sampl size competitor molecul
aim conveni self-administ
subcutan inject soliri pnh ahu
patient need travel clinic everi two week receiv
infus medicin subcutan less
frequent dose would reliev larg burden patient
soliri strong efficaci creat high bar new entrant
akari least year away pivot
phase result alexion next-gener platform
quickli progress develop next-gener
soliri expect extend dose frequenc
eight-week interv longer market
launch expect earli believ
higher probabl success receptor/monoclon
antibodi interact alreadi prove success
mechan target complement system soliri
compani also suit candid target
differ part
complement cascad
subcutan inject early-stag develop
high level cash gener alexion capac
buy two smaller competitor need
competitor even alexion extent face longer
timelin challeng enrol regulatori
drug live normal near-norm life span
chronic natur alexion target diseas grow
patient popul better surviv rate mean
market pnh ahu lal-d expand
compani strong patent portfolio limit risk
biosimilar competit given attract diseas market
alexion oper surpris competitor
clamor enter space compani
well insul lengthi patent portfolio intang
asset underpin alexion narrow moat rest heavili
patent soliri previous extend
european market unit state
recent patent addit take timelin even
opportun lengthen patent life alexion portfolio
earliest gener competit erod strensiq
sale would
drug
composition-of-matt patent expir kanuma
orphan drug exclus european union
respect addit viabl
soliri biosimilar competitor initi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
test soliri
addit autoimmun
indic includ patient neuromyel optica
spectrum disord refractori myasthenia gravi
howev believ soliri expans differ
diseas indic merit posit moat trend
expect biosimilar competitor would abl
quickli gain approv relev indic
mechan action prove safe effect one
alexion sale could also face drastic brand eros
competitor drug reach market subcutan
administr top similar efficaci safeti profil
soliri howev believ alexion long-act
candid although subcutan
inject reach market first provid
attract profil less frequent dose proven
mechan action alexion also subcutan
version early-stag develop
gener would like see opportun
diversif greater acceler pipelin
develop upgrad alexion posit moat
condit clinic trial given rariti diseas
avail effect treatment
launch alexion first-gener product howev
alexion ad benefit already-establish
patient investig relationship leverag
acceler enrol timelin commerci
roll-out product addit alexion special
salesforc strong entrench patient
doctor allow maintain quasi-monopoli
nich diseas area forese futur given
averag doctor never encount patient
one ultra-rar diseas career take uniqu
strategi identifi invest time money
educ correct contact believ alexion hold
lead posit lucr autoimmun metabol
ultra-rare-diseas market forese futur
perspect grow pipelin competitor
complement-medi diseas space balanc
alexion portfolio next-gener candid
stabl trend rate rest abil alexion
pipelin asset stay one step ahead major competit
compani demonstr abil intern develop
complement-rel drug like soliri success
commerci seen launch strensiq give us
confid alexion pipelin complement drug
drug strensiq kanuma brand competit
horizon tout long patent protect
keep particular market dynam stabl
forese futur believ alexion diversif
ultra-rar metabol diseas allow firm leverag
commerci infrastructur expertis derisk
sourc revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ogiven statu orphan drug strong efficaci
soliri garner one highest price tag
payer market share
opnh ahu rare diseas alexion
alreadi identifi easili identifi
patient soliri high growth rate could level
firm unabl expand new market
oalexion abl leverag rare-diseas
expertis infrastructur effici expand
result rise profit margin time
indic
oalexion solid balanc sheet grow cash
balanc provid financi flexibl
abil fund pipelin possibl
owith one highest price tag soliri could
becom target drug price concern could
encount increas price pressur futur
oalexion overpaid synageva acquisit
could depress return invest capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
alexion strong free cash flow gener thank
billion cash cash equival market
secur follow announc billion
acquisit synageva alexion ad billion
debt financ transact current debt level hover
around billion confid compani
abil pay servic debt next
year believ sale soliri franchis
suffici fund intern capit requir includ
clinic pipelin
advanc
commerci
market portfolio
forese futur anticip compani
priorit business-develop activ bolster
alexion face high degre product concentr
risk ad diversif strensiq kanuma
reduc alexion depend soliri
anticip metabol portfolio sale drastic lower
alexion product concentr forecast
soliri sale still account total product
revenu nearli compound
risk investig soliri sale practic late
probe
potenti fraudul
diagnos brazilian polic soliri commerci
success could stunt high price point meet payer
resist also increas rhetor
around drug price congress histor
lacklust develop drug polici passabl
effect howev rise high-deduct
plan scrutini health cost drug price
market may face pressur futur
account nearli alexion total sale launch
competitor molecul conveni method
dose could also captur materi portion soliri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market share pois reach market
less frequent intraven dose competit
failur meet timelin could provid window
competitor launch subcutan version
alexion robust clinic program expand soliri
effort recur manufactur issu
concentr risk alexion receiv food drug
administr warn letter addit
observ swiftli
address howev episod highlight risk
compani suppli chain depend one
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
award alexion standard stewardship rate
abrupt departur ceo david hallal cfo vika sinha
late decemb amid soliri sale practic
investig david brennan took lead interim
ludwig hantson appoint ceo march
earli judg hantson think
compani solid hand hantson serv briefli ceo
baxalta rare-diseas drug busi spun
baxter sold shire year later
baxalta hantson senior leader baxter built
pharma career novarti johnson johnson
surpris see hantson clean hous
revamp manag team compani move past
soliri sale practic investig alexion new team
includ paul clanci chief financi offic brian goff
chief commerci offic john orloff head research
develop indrani franchini chief complianc
offic anne-mari law chief human resourc
offic pleas see depth industri
experi new leadership team bring tabl
sale investig result immateri chang
alexion file would consid downgrad
stewardship rate intern control issu persist
posit alexion futur view team
capital-deploy standpoint think alexion
decis acquir enobia pharma synageva
made strateg sens strensiq kanuma fit well
within alexion strategi focus ultra-rar diseas
devast effect current disease-modifi
treatment alexion abl leverag exist
infrastructur market drug work physician
better identifi ultra-rar diseas howev
concern high price compani paid
synageva cautiou overal valu creation
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
deal view compani acquisit wilson
therapeut much fairli price believ
add much need near-term diversif
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
alexion see piec strategi coalesc
healthi first-quart demand soliri -- despit
trial temporarili cannib sale -- addit posit
top-lin result plan acquisit
wilson therapeut reaffirm confid alexion
trajectori updat fair valu estim
narrow-moat firm per share
incorpor optimist sale guidanc
expect second-quart acquisit wilson therapeut
market long spook compani overreli
soliri sale uncertain next-gener soliri readout
appear warm stock news
success pivot trial data
conveni inject per year versu potenti
effect version soliri despit recent boost
compani stock price fair valu estim impli
significantli upsid attract buy
soliri recent label expans type refractori
gener myasthenia gravi autoimmun neuromuscular
diseas support solid year-over-year sale growth
quarter howev number untap pnh ahu
patient also leav consider amount runway
soliri market alon view compani
plan file next-gener unit state
european union stellar pivot result
demonstr noninferior soliri well data
trend support superior efficaci soliri
though found statist signific believ
anticip launch larg derisk
event alexion firm foundat rest futur
soliri franchis model assum
captur soliri patient slightli expand market
drug entic patient previous
deter burden soliri dose schedul
beyond soliri slightli rais estim
metabol drug strensiq continu grow
metabol drug kanuma saw step sale
howev incorpor lumpi time order
tender market sale grew margin expect
kanuma remain low medium term plan
million cash acquisit wilson therapeut
boast one rare-diseas drug phase studi
add much-need diversif alexion think
acquisit price fair model peak probability-adjust
sale near million excit see
fruit alexion
development success diversif
anoth rare diseas confid
stay power alexion complement-medi diseas
franchis compani exposur soliri estim
sale introduc addit risk
chang alexion fve result
guidanc feb
maintain fair valu estim alexion
pharmaceut incorpor fourth-quart result
guidanc model full-year top-lin result
slightli expect off-set
higher-than-anticip oper expens driven
on-going pivot trial continu ramp alexion
portfolio encourag see strong underli
volum demand drive soliri metabol franchis sale
respons manag project slightli
lower estim soliri growth given higher-
than-expect impact on-going pivot trial evalu
alexion next-gener product
competitor molecul soliri sale believ alexion
accord estim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
similar symptom multipl sclerosi provid anoth
growth fourth quarter thank strong underli
demand rare blood diseas paroxysm nocturn
hemoglobinuria atyp hemolyt urem syndrom
compani lead drug also receiv approv
subtyp myasthenia gravi anoth blood disord
estim could provid elig patient
unit state european union label expans
limit impact fourth-quart sale launch
new indic help off-set headwind
on-going trial enrol million impact
sale anticip effect trial enrol
temporari pressur soliri sale
bear fundament growth drug
price pressur project neg impact
expect new normal compani
believ grow patient demand off-set
phenomenon
sale rare metabol diseas drug strensiq kanuma
increas quarter quarter respect
fourth-quart revenu aid time tender
order extent strong patient growth main
driver model oper expens toward
midpoint manag guidanc margin step
prior estim posit pivot result
alexion conveni next-gen soliri pnh patient
infus everi eight week versu everi two week
soliri expect second quarter follow
eu japan submiss second half year
expect next-gen product allow
firm better protect complement franchis pipelin
competit may slightli aid better market penetr
rate part anticip new drug
replac soliri sale data alexion next-gen
subcutan trial expect trial initi second
half year expect entrench
compani moat posit readout soliri
relaps neuromyel optica spectrum disord
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
